VisionPoint Advisory Group
LGND icon

VisionPoint Advisory Group’s Ligand Pharmaceuticals LGND Stock Holding History

VisionPoint Advisory Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$318K Sell
1,018
-25
-2% -$7.39K 0.05% 338
2026
Q2 		$330K Buy
+1,043
New +$246K 0.05% 333

Other funds holding LGND

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Pembroke Management
Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Woodstock Corp
Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return
Isthmus Partners
Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return
Moody National Bank Trust Division
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

VisionPoint Advisory Group's LGND Position: Q3 2026 in Review

VisionPoint Advisory Group reduced its Ligand Pharmaceuticals (LGND) stake by 2.4% in Q3 2026, selling an estimated $7.39K and leaving 1,018 shares worth $318K. The position accounts for 0.05% of the portfolio, ranked #338.

VisionPoint Advisory Group first reported a position in LGND in Q2 2026 and has held it in 2 quarters since. The position peaked at $330K in Q2 2026. 74 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • VisionPoint Advisory Group held 1,018 shares of Ligand Pharmaceuticals worth $318K as of Q3 2026.
  • VisionPoint Advisory Group sold 25 Ligand Pharmaceuticals shares in Q3 2026, an estimated $7.39K.
  • Ligand Pharmaceuticals made up 0.05% of VisionPoint Advisory Group's portfolio in Q3 2026, its #338 holding.
  • VisionPoint Advisory Group first reported a position in Ligand Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • VisionPoint Advisory Group's Ligand Pharmaceuticals position peaked at $330K in Q2 2026.
  • 74 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on VisionPoint Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.